NEW YORK (Reuters Health) – Adding the anti-VEGF monoclonal antibody bevacizumab to state-of-the-art adjuvant chemotherapy for stage II or III colon cancer does not improve disease-free survival, according…
NEW YORK (Reuters Health) – Patients with age-related macular degeneration treated with the anti-VEGF monoclonal antibodies bevacizumab and ranibizumab do not have any higher rates of mortality, MI…
NEW YORK (Reuters Health) – Rofecoxib used as adjuvant therapy does not improve survival or reduce recurrences in patients who have undergone surgery for colorectal cancer, according to…
NEW YORK (Reuters Health) – For women who have undergone laparoscopic surgery for severe endometriosis, ongoing chronic pelvic pain is relieved with use of the levonorgestrel-releasing intrauterine system…
NEW YORK (Reuters Health) – Mortality in acute coronary syndromes is no lower among those taking aspirin before the event than in non-aspirin users. This apparent “aspirin paradox”…
NEW YORK (Reuters Health) – There’s a 25% chance that patients with hypersensitivity to cephalosporins will also react to penicillins, a European group reports, but the risk with…
NEW YORK (Reuters Health) – The use of inhaled corticosteroids, whether for asthma or chronic obstructive pulmonary disease (COPD), increases the likelihood of diabetes onset and diabetes progression,…
NEW YORK (Reuters Health) – Patients with bipolar disorder treated with more than one second-generation antipsychotic drug do not do any better than those treated with one drug,…
NEW YORK (Reuters Health) – Patients with overactive bladder (OAB) may do better with fesoterodine 8 mg/d than with tolterodine extended release 4mg/d, according to the results of…
NEW YORK (Reuters Health) – The high case mortality rate associated with H5N1 avian influenza in humans can be significantly reduced with oseltamivir therapy, even when started a…